Cytokinetics, Incorporated (CYTK)
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capital Markets.
Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript
Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago.
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
